The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
Zacks Investment Research on MSN3d
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits FailureThis week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a buyout and high-dose Ocrevus missed a study goal.
BofA analyst Jason Zemansky lowered the firm’s price target on Travere Therapeutics (TVTX) to $27 from $31 and keeps a Buy rating on the shares ...
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...
The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.
Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback